Loading clinical trials...
Loading clinical trials...
A Double-blind, Randomized, Placebo-controlled, Sequential Group Pilot Study to Assess Safety, Tolerability, and Effectiveness of TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension
Conditions
Interventions
Placebo
TC-5214
Locations
1
United States
Piedmont Medical Research
Winston-Salem, North Carolina, United States
Start Date
May 1, 2009
Primary Completion Date
August 1, 2009
Completion Date
December 1, 2009
Last Updated
September 13, 2013
Lead Sponsor
Targacept Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions